Co-Authors
This is a "connection" page, showing publications co-authored by SANJEEV VASUDEVAN and SARAH WOODFIELD.
Connection Strength
3.340
-
HepT1-derived murine models of high-risk hepatoblastoma display vascular invasion, metastasis, and circulating tumor cells. Biol Open. 2022 09 15; 11(9).
Score: 0.802
-
An indocyanine green-based liquid biopsy test for circulating tumor cells for pediatric liver cancer. Hepatol Commun. 2024 06 01; 8(6).
Score: 0.225
-
Histopathologic and immunophenotypic characterization of patient-derived pediatric malignant hepatocellular tumor xenografts (PDXs). Pathol Res Pract. 2024 Mar; 255:155163.
Score: 0.221
-
A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma. J Hepatol. 2024 04; 80(4):610-621.
Score: 0.220
-
Navigating relapsed hepatoblastoma: Predictive factors and surgical treatment strategy. Cancer Med. 2023 12; 12(23):21270-21278.
Score: 0.217
-
An indocyanine green-based liquid biopsy test for circulating tumor cells for pediatric liver cancer. bioRxiv. 2023 Jul 05.
Score: 0.212
-
Author Correction: MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 Oct 01; 11(1):19916.
Score: 0.188
-
MDM4 inhibition: a novel therapeutic strategy to reactivate p53 in hepatoblastoma. Sci Rep. 2021 02 03; 11(1):2967.
Score: 0.179
-
Animal Modeling of Pediatric Liver Cancer. Cancers (Basel). 2020 Jan 22; 12(2).
Score: 0.167
-
Targeting LRH-1 in hepatoblastoma cell lines causes decreased proliferation. Oncol Rep. 2019 Jan; 41(1):143-153.
Score: 0.153
-
A Novel Cell Line Based Orthotopic Xenograft Mouse Model That Recapitulates Human Hepatoblastoma. Sci Rep. 2017 12 19; 7(1):17751.
Score: 0.144
-
Oncogenic Role of Aberrant EZH2 in Hepatoblastoma. bioRxiv. 2025 Aug 01.
Score: 0.061
-
Coordinated regulation by lncRNAs results in tight lncRNA-target couplings. Cell Genom. 2025 Aug 13; 5(8):100927.
Score: 0.061
-
Asynchronous Transitions from Hepatoblastoma to Carcinoma in High-Risk Pediatric Tumors. bioRxiv. 2024 Dec 27.
Score: 0.059
-
A humanized mouse model for adeno-associated viral gene therapy. Nat Commun. 2024 Mar 04; 15(1):1955.
Score: 0.056
-
Quantitative ctDNA Detection in Hepatoblastoma: Implications for Precision Medicine. Cancers (Basel). 2023 Dec 19; 16(1).
Score: 0.055
-
Development of Iodinated Indocyanine Green Analogs as a Strategy for Targeted Therapy of Liver Cancer. ACS Med Chem Lett. 2023 Sep 14; 14(9):1208-1215.
Score: 0.054
-
Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults. J Hepatol. 2022 10; 77(4):1026-1037.
Score: 0.049
-
Small molecule inhibitor agerafenib effectively suppresses neuroblastoma tumor growth in mouse models via inhibiting ERK MAPK signaling. Cancer Lett. 2019 08 10; 457:129-141.
Score: 0.040
-
Inhibition of Ubiquitin-Specific Protease 14 Suppresses Cell Proliferation and Synergizes with Chemotherapeutic Agents in Neuroblastoma. Mol Cancer Ther. 2019 06; 18(6):1045-1056.
Score: 0.040
-
Small molecule inhibitor regorafenib inhibits RET signaling in neuroblastoma cells and effectively suppresses tumor growth in vivo. Oncotarget. 2017 Nov 28; 8(61):104090-104103.
Score: 0.036
-
EWS-FLI1 and RNA helicase A interaction inhibitor YK-4-279 inhibits growth of neuroblastoma. Oncotarget. 2017 Nov 07; 8(55):94780-94792.
Score: 0.036
-
Novel multi-targeted ErbB family inhibitor afatinib blocks EGF-induced signaling and induces apoptosis in neuroblastoma. Oncotarget. 2017 Jan 03; 8(1):1555-1568.
Score: 0.034
-
Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling. Oncotarget. 2017 Jan 03; 8(1):1469-1480.
Score: 0.034